Top Markets
Coin of the day
Scandion Oncology A/S Scandion Oncology A/S

Scandion Oncology A/S

SCOL
Rank in Stocks #40631
Operating as a clinical-stage biotechnology company, Scandion Oncology A/S... Operating as a clinical-stage biotechnology company, Scandion Oncology A/S specializes in creating pharmaceutical solutions to combat resistance to chemotherapy. Their primary investigational drug, SCO-101, an orally administered compound, is currently progressing through Phase Ib and Phase II clinical studies with cancer patients. Another pipeline candidate, SCO-201, is undergoing preclinical assessment for its potential efficacy against solid tumors. Established in 2017, Scandion Oncology A/S maintains its headquarters in Copenhagen, Denmark.
Share Price
$0.00045794
Last synced: 2025-07-11
Market Cap
$107.51K
Change (1 day)
-36.01%
Change (1 year)
0.00%
Country
DK
Trade Scandion Oncology A/S (SCOL)

Category

EPS for Scandion Oncology A/S (SCOL)
EPS as of 2026 TTM: 0
According to Scandion Oncology A/S latest financial reports and stock price the company's current EPS (TTM) is 0. At the end of 2026 the company had a EPS of 0 equal to its 2026 EPS that were of 0.
EPS history for Scandion Oncology A/S from 2026 to 2026
EPS at the end of each year
Year EPS Change
Not enough data for the provided dates.
EPS for similar companies or competitors
Company EPS EPS Difference Country
$17.32 -
US
$27.74 -
NL
- -
CH
- -
KR
$13.70 -
BE